Samit Hirawat, Bristol Myers Squibb CMO (Bristol Myers)

Bris­tol My­ers cel­e­brates a big win with FDA ap­proval of $13B car­dio drug mava­camten

Af­ter get­ting hit with an FDA de­lay back in No­vem­ber, Bris­tol My­ers Squibb is fi­nal­ly cel­e­brat­ing a win for mava­camten, the cen­ter­piece of the com­pa­ny’s $13 bil­lion MyoKar­dia buy­out back in 2020.

Reg­u­la­tors ap­proved mava­camten on Thurs­day to treat symp­to­matic ob­struc­tive hy­per­trophic car­diomy­opa­thy, or oHCM: a con­di­tion in which the mus­cu­lar wall be­tween the two bot­tom cham­bers of the heart be­comes thick­er than nor­mal, block­ing blood flow out of the heart.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters